Pharmacology and the Nursing
Process
10th Edition
• Author(s)Linda Lane Lilley;
Shelly Rainforth Collins; Julie
S. Snyder
TEST BANK
,Question 1: Multiple-Choice Question (MCQ)
1. Question Number and Item Type
• Question Number: Q1
• Item Type: Multiple-Choice Question (MCQ)
2. Clinical Scenario
A 42-year-old male patient with a history of chronic severe back
pain is being transitioned from an intravenous (IV) opioid
infusion to an oral (PO) extended-release formulation of the
same medication before discharge. The nurse notes that the
prescribed oral dose is significantly higher than the total 24-
hour intravenous dose the patient was receiving.
3. Question Stem
Which pharmacokinetic principle best explains to the nurse why
the oral dose must be substantially higher than the intravenous
dose to achieve equivalent therapeutic effects?
• A) High protein binding capacity of the oral formulation in
the systemic circulation.
• B) The extensive first-pass hepatic metabolism that occurs
following oral ingestion.
• C) Accelerated renal clearance secondary to
gastrointestinal tract activation.
, • D) Reduced subcutaneous tissue distribution of the drug
when taken orally.
4. Answer Options
• A) High protein binding capacity of the oral formulation in
the systemic circulation.
• B) The extensive first-pass hepatic metabolism that occurs
following oral ingestion.
• C) Accelerated renal clearance secondary to
gastrointestinal tract activation.
• D) Reduced subcutaneous tissue distribution of the drug
when taken orally.
5. Correct Answer
B) The extensive first-pass hepatic metabolism that occurs
following oral ingestion.
6. Comprehensive Rationale
When a medication is administered orally, it is absorbed from
the gastrointestinal tract into the portal circulation and passes
directly through the liver via the portal vein before reaching the
systemic circulation. For drugs with a high first-pass effect, a
large fraction of the active drug is metabolized by hepatic
enzymes (such as the cytochrome P450 system) into inactive
metabolites during this initial pass.
, Consequently, the bioavailability (the fraction of the chemically
unchanged drug that reaches systemic circulation) is drastically
reduced compared to intravenous administration, where the
drug enters the systemic venous system directly, bypassing the
liver completely ($100\%$ bioavailability). To achieve equivalent
therapeutic serum levels and ensure effective
pharmacotherapeutics (pain control), the oral dose must be
mathematically adjusted upward to compensate for this hepatic
degradation.
7. Distractor Analysis
• Option A is incorrect: Protein binding affects active drug
distribution and half-life, but it does not differ based solely
on the route of administration for the exact same chemical
compound once inside the plasma.
o Common Clinical Misconception: Believing that oral
drugs bind more tightly to albumin than IV drugs.
o Potential Medication Safety Risk: Miscalculating
equivalent doses based on protein binding ratios,
leading to under-medication.
o Appropriate Nursing Action: Focus on bioavailability
calculations and clinical efficacy metrics during
medication transition.
Process
10th Edition
• Author(s)Linda Lane Lilley;
Shelly Rainforth Collins; Julie
S. Snyder
TEST BANK
,Question 1: Multiple-Choice Question (MCQ)
1. Question Number and Item Type
• Question Number: Q1
• Item Type: Multiple-Choice Question (MCQ)
2. Clinical Scenario
A 42-year-old male patient with a history of chronic severe back
pain is being transitioned from an intravenous (IV) opioid
infusion to an oral (PO) extended-release formulation of the
same medication before discharge. The nurse notes that the
prescribed oral dose is significantly higher than the total 24-
hour intravenous dose the patient was receiving.
3. Question Stem
Which pharmacokinetic principle best explains to the nurse why
the oral dose must be substantially higher than the intravenous
dose to achieve equivalent therapeutic effects?
• A) High protein binding capacity of the oral formulation in
the systemic circulation.
• B) The extensive first-pass hepatic metabolism that occurs
following oral ingestion.
• C) Accelerated renal clearance secondary to
gastrointestinal tract activation.
, • D) Reduced subcutaneous tissue distribution of the drug
when taken orally.
4. Answer Options
• A) High protein binding capacity of the oral formulation in
the systemic circulation.
• B) The extensive first-pass hepatic metabolism that occurs
following oral ingestion.
• C) Accelerated renal clearance secondary to
gastrointestinal tract activation.
• D) Reduced subcutaneous tissue distribution of the drug
when taken orally.
5. Correct Answer
B) The extensive first-pass hepatic metabolism that occurs
following oral ingestion.
6. Comprehensive Rationale
When a medication is administered orally, it is absorbed from
the gastrointestinal tract into the portal circulation and passes
directly through the liver via the portal vein before reaching the
systemic circulation. For drugs with a high first-pass effect, a
large fraction of the active drug is metabolized by hepatic
enzymes (such as the cytochrome P450 system) into inactive
metabolites during this initial pass.
, Consequently, the bioavailability (the fraction of the chemically
unchanged drug that reaches systemic circulation) is drastically
reduced compared to intravenous administration, where the
drug enters the systemic venous system directly, bypassing the
liver completely ($100\%$ bioavailability). To achieve equivalent
therapeutic serum levels and ensure effective
pharmacotherapeutics (pain control), the oral dose must be
mathematically adjusted upward to compensate for this hepatic
degradation.
7. Distractor Analysis
• Option A is incorrect: Protein binding affects active drug
distribution and half-life, but it does not differ based solely
on the route of administration for the exact same chemical
compound once inside the plasma.
o Common Clinical Misconception: Believing that oral
drugs bind more tightly to albumin than IV drugs.
o Potential Medication Safety Risk: Miscalculating
equivalent doses based on protein binding ratios,
leading to under-medication.
o Appropriate Nursing Action: Focus on bioavailability
calculations and clinical efficacy metrics during
medication transition.
